CSL Hit by $7 Billion Blow After Cutting Earnings Forecasts

CSL has entered one of the most difficult periods in its recent history after a sweeping business review forced the healthcare giant to recognise a huge impairment charge and lower its earnings expectations for the 2026 financial year.

The company said it would take a non-cash write-down of about US$5 billion, or roughly A$7 billion, after reassessing the value of parts of its global operations. The announcement immediately unsettled investors, with CSL falling more than 20 per cent in Australian trading and slipping below A$100 for the first time in more than a decade.

The decline is striking because CSL was once treated as one of the ASX’s most dependable long-term growth names. During the pandemic period, the company traded near A$340 as vaccine demand and investor confidence helped lift healthcare valuations. Its latest fall shows how sharply sentiment has reversed as earnings pressure, asset write-downs and leadership uncertainty weigh on the group.

Interim chief executive Gordon Naylor delivered the update after completing a 90-day review of the business. Naylor took charge after former chief executive Paul McKenzie left the company, and his first major assessment has made clear that CSL’s recovery will not be as quick as investors had hoped.

The write-down includes pressure linked to CSL’s Vifor kidney treatment business, as well as weaker conditions in two important international areas. CSL flagged a further US$300 million hit connected to its US immunoglobulin operations and another US$200 million impact tied to its albumin business in China.

Those details matter because they point to pressure across several parts of the group rather than one isolated setback. Immunoglobulin is a key part of CSL’s plasma-based business, while China has been an important growth market for albumin. Weakness in both areas makes the company’s earnings recovery more complicated.

CSL now expects full-year revenue of around US$15.1 billion to US$15.2 billion. Net profit is expected to be about US$3.1 billion, lower than earlier expectations closer to US$3.3 billion. The downgrade was especially damaging because the company had reaffirmed its outlook only months earlier, making the scale of the revision harder for shareholders to absorb.

The company has published its latest financial update through its official investor relations page, where investors can track CSL’s announcements and financial reports directly.

Naylor argued that CSL’s growth plans are still moving in the right direction, but he acknowledged that the benefits will take longer to show up in financial results. That message may be reasonable from a management perspective, but the market’s response suggests investors want clearer evidence rather than fresh promises.

The downgrade also follows a painful restructuring announced last year, when CSL revealed plans to cut 3000 jobs worldwide. The company said the program would cost about US$770 million at first but could eventually generate annual savings of US$500 million to US$550 million over three years.

CSL is also preparing to separate Seqirus, its influenza vaccines business, into a standalone ASX-listed company in 2026. The planned demerger is designed to simplify the group and allow investors to value the vaccine business separately from CSL’s core plasma and specialty medicine operations.

At the same time, CSL is combining the commercial and medical operations of its blood plasma and iron deficiency businesses. The move is part of a broader attempt to streamline decision-making and improve efficiency, but the latest downgrade shows that restructuring alone has not yet solved the earnings problem.

Leadership remains another concern. Naylor has said the search for a permanent chief executive is continuing and could take up to a year. He is not expected to be a candidate for the permanent role. CSL also announced that chief commercial officer Andy Schmeltz will retire, with Diego Sacristan set to take over the role from July 1 after leading CSL Behring’s US operations.

The board is now under pressure to show that the company has a clear plan for rebuilding investor trust. Chairman Brian McNamee, a former long-serving CSL chief executive, faces questions over succession planning and the company’s strategic direction after a series of disappointing updates.

One important point is that the impairment is non-cash. That means it does not directly drain CSL’s bank account in the way an operating loss or cash expense would. However, a write-down of this size still carries weight because it signals that some assets are now expected to deliver less value than previously assumed.

For investors, the issue is not just the accounting charge. The deeper concern is whether CSL can restore steady earnings growth after weaker plasma margins, lower US vaccine demand and pressure in acquired businesses. The company’s reputation was built on consistency, and that consistency is now being tested.

CSL said it does not expect a material impact from US pharmaceutical tariffs, as its life-saving medicines are expected to be exempt. That gives the company some relief on trade risk, but it does not remove the larger questions around execution and demand.

The sell-off also adds to broader pressure across ASX healthcare names, where investors have become less forgiving when companies miss guidance. Swikblog recently covered similar market sensitivity in Cochlear’s sharp decline after a profit warning, showing how quickly confidence can fade when earnings expectations change.

CSL still has valuable global healthcare franchises, deep scientific expertise and a strong presence in plasma-derived therapies. Its products remain important for patients, and the company is not facing a demand collapse across the whole business. But after this latest update, investors are likely to judge CSL less on its past reputation and more on whether management can deliver visible improvement.

The next stage will be crucial. Markets will want evidence that Vifor is stabilising, that plasma growth can recover, that China weakness is manageable and that restructuring savings are flowing through without damaging the business. Until that happens, CSL may struggle to regain the premium valuation it once enjoyed.

For now, the message from investors is clear. CSL’s long-term story is not over, but patience has thinned. After a US$5 billion impairment, lower earnings guidance and another major share price fall, the healthcare giant must now prove that its turnaround is more than a plan on paper.